Abstract
Summary
Sartan-series drugs are one of the commonly used clinical antihypertensive drugs, ending with "sartan", such as losartan, valsartan, telmisartan, also known as angiotensin II receptor antagonists or Angiotensin receptor blocker (ARBs). They include irbesartan, valsartan, losartan and candesartan. If the name of a medicine ends in ‘sartan’, it is an ARB.
The global Sartan-series Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “Sartan-series Drugs Industry Forecast” looks at past sales and reviews total world Sartan-series Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Sartan-series Drugs sales for 2023 through 2029. With Sartan-series Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sartan-series Drugs industry.
This Insight Report provides a comprehensive analysis of the global Sartan-series Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Sartan-series Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sartan-series Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sartan-series Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sartan-series Drugs.
United States market for Sartan-series Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Sartan-series Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Sartan-series Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Sartan-series Drugs players cover Novartis, Merck & Co, Sanofi, Pfizer, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Sartan-series Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others
Segmentation by Application:
Hospital Pharmaty
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others
Segmentation by Application:
Hospital Pharmaty
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Merck & Co
Sanofi
Pfizer
Bayer
AstraZeneca
Daiichi Sankyo
Takeda
Bristol-Myers Squibb Company
Boehringer Ingelheim
Abbott
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
The global Sartan-series Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “Sartan-series Drugs Industry Forecast” looks at past sales and reviews total world Sartan-series Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Sartan-series Drugs sales for 2023 through 2029. With Sartan-series Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sartan-series Drugs industry.
This Insight Report provides a comprehensive analysis of the global Sartan-series Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Sartan-series Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sartan-series Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sartan-series Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sartan-series Drugs.
United States market for Sartan-series Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Sartan-series Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Sartan-series Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Sartan-series Drugs players cover Novartis, Merck & Co, Sanofi, Pfizer, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Sartan-series Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others
Segmentation by Application:
Hospital Pharmaty
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others
Segmentation by Application:
Hospital Pharmaty
Retail Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Merck & Co
Sanofi
Pfizer
Bayer
AstraZeneca
Daiichi Sankyo
Takeda
Bristol-Myers Squibb Company
Boehringer Ingelheim
Abbott
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Sartan-series Drugs Market Size 2019-2030
2.1.2 Sartan-series Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Sartan-series Drugs by Country/Region, 2019, 2023 & 2030
2.2 Sartan-series Drugs Segment by Type
2.2.1 Losartan
2.2.2 Valsartan
2.2.3 Irbesartan
2.2.4 Telmisartan
2.2.5 Olmesartan
2.2.6 Candesartan
2.2.7 Sacubitril/valsartan
2.2.8 Others
2.3 Sartan-series Drugs Market Size by Type
2.3.1 Sartan-series Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Sartan-series Drugs Market Size Market Share by Type (2019-2024)
2.4 Sartan-series Drugs Segment by Application
2.4.1 Hospital Pharmaty
2.4.2 Retail Pharmacy
2.5 Sartan-series Drugs Market Size by Application
2.5.1 Sartan-series Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Sartan-series Drugs Market Size Market Share by Application (2019-2024)
3 Sartan-series Drugs Market Size by Player
3.1 Sartan-series Drugs Market Size Market Share by Player
3.1.1 Global Sartan-series Drugs Revenue by Player (2019-2024)
3.1.2 Global Sartan-series Drugs Revenue Market Share by Player (2019-2024)
3.2 Global Sartan-series Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Sartan-series Drugs by Region
4.1 Sartan-series Drugs Market Size by Region (2019-2024)
4.2 Global Sartan-series Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Sartan-series Drugs Market Size Growth (2019-2024)
4.4 APAC Sartan-series Drugs Market Size Growth (2019-2024)
4.5 Europe Sartan-series Drugs Market Size Growth (2019-2024)
4.6 Middle East & Africa Sartan-series Drugs Market Size Growth (2019-2024)
5 Americas
5.1 Americas Sartan-series Drugs Market Size by Country (2019-2024)
5.2 Americas Sartan-series Drugs Market Size by Type (2019-2024)
5.3 Americas Sartan-series Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Sartan-series Drugs Market Size by Region (2019-2024)
6.2 APAC Sartan-series Drugs Market Size by Type (2019-2024)
6.3 APAC Sartan-series Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Sartan-series Drugs Market Size by Country (2019-2024)
7.2 Europe Sartan-series Drugs Market Size by Type (2019-2024)
7.3 Europe Sartan-series Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Sartan-series Drugs by Region (2019-2024)
8.2 Middle East & Africa Sartan-series Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Sartan-series Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Sartan-series Drugs Market Forecast
10.1 Global Sartan-series Drugs Forecast by Region (2025-2030)
10.1.1 Global Sartan-series Drugs Forecast by Region (2025-2030)
10.1.2 Americas Sartan-series Drugs Forecast
10.1.3 APAC Sartan-series Drugs Forecast
10.1.4 Europe Sartan-series Drugs Forecast
10.1.5 Middle East & Africa Sartan-series Drugs Forecast
10.2 Americas Sartan-series Drugs Forecast by Country (2025-2030)
10.2.1 United States Market Sartan-series Drugs Forecast
10.2.2 Canada Market Sartan-series Drugs Forecast
10.2.3 Mexico Market Sartan-series Drugs Forecast
10.2.4 Brazil Market Sartan-series Drugs Forecast
10.3 APAC Sartan-series Drugs Forecast by Region (2025-2030)
10.3.1 China Sartan-series Drugs Market Forecast
10.3.2 Japan Market Sartan-series Drugs Forecast
10.3.3 Korea Market Sartan-series Drugs Forecast
10.3.4 Southeast Asia Market Sartan-series Drugs Forecast
10.3.5 India Market Sartan-series Drugs Forecast
10.3.6 Australia Market Sartan-series Drugs Forecast
10.4 Europe Sartan-series Drugs Forecast by Country (2025-2030)
10.4.1 Germany Market Sartan-series Drugs Forecast
10.4.2 France Market Sartan-series Drugs Forecast
10.4.3 UK Market Sartan-series Drugs Forecast
10.4.4 Italy Market Sartan-series Drugs Forecast
10.4.5 Russia Market Sartan-series Drugs Forecast
10.5 Middle East & Africa Sartan-series Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Market Sartan-series Drugs Forecast
10.5.2 South Africa Market Sartan-series Drugs Forecast
10.5.3 Israel Market Sartan-series Drugs Forecast
10.5.4 Turkey Market Sartan-series Drugs Forecast
10.6 Global Sartan-series Drugs Forecast by Type (2025-2030)
10.7 Global Sartan-series Drugs Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Sartan-series Drugs Forecast
11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Sartan-series Drugs Product Offered
11.1.3 Novartis Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Merck & Co
11.2.1 Merck & Co Company Information
11.2.2 Merck & Co Sartan-series Drugs Product Offered
11.2.3 Merck & Co Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Merck & Co Main Business Overview
11.2.5 Merck & Co Latest Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Sartan-series Drugs Product Offered
11.3.3 Sanofi Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Sanofi Main Business Overview
11.3.5 Sanofi Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Sartan-series Drugs Product Offered
11.4.3 Pfizer Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Bayer
11.5.1 Bayer Company Information
11.5.2 Bayer Sartan-series Drugs Product Offered
11.5.3 Bayer Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Bayer Main Business Overview
11.5.5 Bayer Latest Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Company Information
11.6.2 AstraZeneca Sartan-series Drugs Product Offered
11.6.3 AstraZeneca Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 AstraZeneca Main Business Overview
11.6.5 AstraZeneca Latest Developments
11.7 Daiichi Sankyo
11.7.1 Daiichi Sankyo Company Information
11.7.2 Daiichi Sankyo Sartan-series Drugs Product Offered
11.7.3 Daiichi Sankyo Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Daiichi Sankyo Main Business Overview
11.7.5 Daiichi Sankyo Latest Developments
11.8 Takeda
11.8.1 Takeda Company Information
11.8.2 Takeda Sartan-series Drugs Product Offered
11.8.3 Takeda Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Takeda Main Business Overview
11.8.5 Takeda Latest Developments
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Information
11.9.2 Bristol-Myers Squibb Company Sartan-series Drugs Product Offered
11.9.3 Bristol-Myers Squibb Company Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Bristol-Myers Squibb Company Main Business Overview
11.9.5 Bristol-Myers Squibb Company Latest Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Information
11.10.2 Boehringer Ingelheim Sartan-series Drugs Product Offered
11.10.3 Boehringer Ingelheim Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Boehringer Ingelheim Main Business Overview
11.10.5 Boehringer Ingelheim Latest Developments
11.11 Abbott
11.11.1 Abbott Company Information
11.11.2 Abbott Sartan-series Drugs Product Offered
11.11.3 Abbott Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Abbott Main Business Overview
11.11.5 Abbott Latest Developments
11.12 Teva Pharmaceutical
11.12.1 Teva Pharmaceutical Company Information
11.12.2 Teva Pharmaceutical Sartan-series Drugs Product Offered
11.12.3 Teva Pharmaceutical Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Teva Pharmaceutical Main Business Overview
11.12.5 Teva Pharmaceutical Latest Developments
11.13 Shenzhen Salubris Pharmaceuticals
11.13.1 Shenzhen Salubris Pharmaceuticals Company Information
11.13.2 Shenzhen Salubris Pharmaceuticals Sartan-series Drugs Product Offered
11.13.3 Shenzhen Salubris Pharmaceuticals Sartan-series Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Shenzhen Salubris Pharmaceuticals Main Business Overview
11.13.5 Shenzhen Salubris Pharmaceuticals Latest Developments
12 Research Findings and Conclusion